Skip to main content
. 2009 Jul 21;101(3):418–423. doi: 10.1038/sj.bjc.6605092

Figure 2.

Figure 2

Treatment with ZD4190 reduced the area and microvascularity of tumour foci in a muscle model of minimal residual carcinoma. ZD4190 reduced (A) the tumour area at day 22 when more than 105 PDVC57B cells were implanted to create each tract in the rectus and gastrocnemius muscles for groups of mice (n=5) and (B) the MVD of the tracts that developed in the gastrocnemius at day 9 and at both sites at day 22.